BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Franzoi MA, Vandeputte C, Eiger D, Caparica R, Brandão M, De Angelis C, Hendlisz A, Awada A, Piccart M, de Azambuja E. Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors. Breast Cancer Res Treat 2020;181:199-209. [PMID: 32246377 DOI: 10.1007/s10549-020-05617-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Luo L, Shen X, Fang S, Wan T, Liu P, Li P, Tan H, Fu Y, Guo W, Tang X. Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis. BMC Cancer 2023;23:127. [PMID: 36750774 DOI: 10.1186/s12885-023-10582-2] [Reference Citation Analysis]
2 Zhou M, Shen X, Fang S, Wan T, Liu P, Li P, Tan H, Fu Y, Guo W. Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis.. [DOI: 10.21203/rs.3.rs-2319788/v1] [Reference Citation Analysis]
3 Cheng E, Caan BJ, Chen WY, Irwin ML, Prado CM, Cespedes Feliciano EM. Adipose tissue radiodensity and mortality among patients with nonmetastatic breast cancer. Clin Nutr 2022;41:2607-13. [PMID: 36306565 DOI: 10.1016/j.clnu.2022.09.016] [Reference Citation Analysis]
4 Kripa E, Rizzo V, Galati F, Moffa G, Cicciarelli F, Catalano C, Pediconi F. Do body composition parameters correlate with response to targeted therapy in ER+/HER2- metastatic breast cancer patients? Role of sarcopenia and obesity. Front Oncol 2022;12:987012. [DOI: 10.3389/fonc.2022.987012] [Reference Citation Analysis]
5 Cheng E, Kirley J, Cespedes Feliciano EM, Caan BJ. Adiposity and cancer survival: a systematic review and meta-analysis. Cancer Causes Control 2022. [PMID: 35971021 DOI: 10.1007/s10552-022-01613-7] [Reference Citation Analysis]
6 Poltronieri TS, Pérsico RS, Falcetta FS, Viana LV. Changes in Body Adiposity in Women Undergoing Breast Cancer Treatment: A Scoping Review. Nutrition and Cancer. [DOI: 10.1080/01635581.2022.2081341] [Reference Citation Analysis]
7 Tang R, Deng JP, Zhang L, Zhang WW, Sun JY, Chi F, Zhang J, Wu SG, He ZY. Prognostic significance of the skeletal muscle index and systemic inflammatory index in patients with lymph node-positive breast cancer after radical mastectomy. BMC Cancer 2022;22:234. [PMID: 35241010 DOI: 10.1186/s12885-022-09312-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Palleschi M, Prochowski Iamurri A, Scarpi E, Mariotti M, Maltoni R, Mannozzi F, Barone D, Paganelli G, Casi M, Giampalma E, De Giorgi U, Rocca A. Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab. Sci Rep 2022;12:3385. [PMID: 35233007 DOI: 10.1038/s41598-022-07143-1] [Reference Citation Analysis]
9 Barone I, Caruso A, Gelsomino L, Giordano C, Bonofiglio D, Catalano S, Andò S. Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives. Obes Rev 2022;23:e13358. [PMID: 34559450 DOI: 10.1111/obr.13358] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
10 Franzoi MA, Lambertini M, Ceppi M, Bruzzone M, de Azambuja E. Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients. Breast Cancer Res Treat. [DOI: 10.1007/s10549-022-06525-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Tolonen A, Pakarinen T, Sassi A, Kyttä J, Cancino W, Rinta-Kiikka I, Pertuz S, Arponen O. Methodology, clinical applications, and future directions of body composition analysis using computed tomography (CT) images: A review. Eur J Radiol 2021;145:109943. [PMID: 34839215 DOI: 10.1016/j.ejrad.2021.109943] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
12 Franzoi MA, Eiger D, Ameye L, Ponde N, Caparica R, De Angelis C, Brandão M, Desmedt C, Di Cosimo S, Kotecki N, Lambertini M, Awada A, Piccart M, Azambuja E. Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy. J Natl Cancer Inst 2021;113:462-70. [PMID: 32750143 DOI: 10.1093/jnci/djaa116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
13 Delrieu L, Martin A, Touillaud M, Pérol O, Morelle M, Febvey-Combes O, Freyssenet D, Friedenreich C, Dufresne A, Bachelot T, Heudel PE, Trédan O, Crochet H, Bouhamama A, Pilleul F, Pialoux V, Fervers B. Sarcopenia and serum biomarkers of oxidative stress after a 6-month physical activity intervention in women with metastatic breast cancer: results from the ABLE feasibility trial. Breast Cancer Res Treat 2021;188:601-13. [PMID: 34013451 DOI: 10.1007/s10549-021-06238-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]